PMID- 27864686
OWN - NLM
STAT- MEDLINE
DCOM- 20170329
LR  - 20220409
IS  - 1179-1950 (Electronic)
IS  - 0012-6667 (Linking)
VI  - 76
IP  - 17
DP  - 2016 Nov
TI  - Zoledronic Acid (Reclast((R)), Aclasta((R))): A Review in Osteoporosis.
PG  - 1683-1697
AB  - Zoledronic acid (Reclast((R)), Aclasta((R))) is an intravenous, highly potent 
      aminobisphosphonate approved worldwide, including in the USA, EU and Japan for 
      use in patients with primary or secondary osteoporosis or low bone mass (approved 
      indications vary between countries). Its high affinity to and long half-life in 
      bone, and long duration of action, allow for once-yearly administration, which 
      has the potential to improve adherence to therapy. Zoledronic acid once yearly 
      for up to 3 years improved bone mineral density (BMD) at several skeletal sites, 
      reduced fracture risk and bone turnover, and/or preserved bone structure and mass 
      relative to placebo in clinical studies in patients with primary or secondary 
      osteoporosis. While additional benefits were seen when treatment was continued 
      for up to 6 years, as evidenced by a reduced risk of vertebral fractures and 
      higher BMD relative to 3 years' therapy, there was minimal advantage of treatment 
      beyond 6 years. Therefore, in patients with low fracture risk, treatment 
      discontinuation should be considered after approximately 5 years' therapy. 
      Zoledronic acid administered annually or once in 2 years was also effective in 
      preventing bone loss in patients with low bone mass. Zoledronic acid was 
      generally well tolerated, with the most common adverse events (AEs) being 
      transient, mild-to-moderate post-infusion symptoms, which decreased with 
      subsequent infusions. To conclude, zoledronic acid once yearly is an effective 
      and generally well tolerated treatment option for patients with osteoporosis.
FAU - Dhillon, Sohita
AU  - Dhillon S
AD  - Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand. 
      demail@springer.com.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Drugs
JT  - Drugs
JID - 7600076
RN  - 0 (Bone Density Conservation Agents)
RN  - 0 (Diphosphonates)
RN  - 0 (Imidazoles)
RN  - 6XC1PAD3KF (Zoledronic Acid)
SB  - IM
MH  - Animals
MH  - Bone Density/drug effects
MH  - Bone Density Conservation Agents/*pharmacology/*therapeutic use
MH  - Diphosphonates/*pharmacology/*therapeutic use
MH  - Fractures, Bone/drug therapy
MH  - Humans
MH  - Imidazoles/*pharmacology/*therapeutic use
MH  - Osteoporosis/*drug therapy
MH  - Zoledronic Acid
EDAT- 2016/11/20 06:00
MHDA- 2017/03/31 06:00
CRDT- 2016/11/20 06:00
PHST- 2016/11/20 06:00 [pubmed]
PHST- 2017/03/31 06:00 [medline]
PHST- 2016/11/20 06:00 [entrez]
AID - 10.1007/s40265-016-0662-4 [pii]
AID - 10.1007/s40265-016-0662-4 [doi]
PST - ppublish
SO  - Drugs. 2016 Nov;76(17):1683-1697. doi: 10.1007/s40265-016-0662-4.